摘要
目的:研究人着色性干皮病G组(XPG)C46T与奥沙利铂治疗晚期胃癌敏感性的关系。方法:用REAL-TIMEPCR技术检测92例晚期胃癌患者外周静脉血DNA的XPG基因的单核苷多态性(SNP)分型。比较三种基因型与奥沙利铂化疗后患者的2周期化疗临床疗效、中位疾病进展时间(TTP)的关系。结果:92例患者的C/C、T/T、C/T基因型分别为51.09%(47/92)、38.04%(35/92)、10.87%(10/92),C/C与T/T+C/T基因型2周期临床获益率和中位TTP分别为76.59%、6个月和53.33%、4个月,C/C基因型的临床获益率和中位TTP均优于T/T+C/T基因型。结论:XPG基因多态性与奥沙利铂疗效之间存在相关性,其检测结果可以指导胃癌选择奥沙利铂化疗。
Objective:To investigate the relationship between polymorphisms in XPG gene C46T and therapeutic effect of oxaliplatin for advanced gastric cancer.Methods:The types of XPG single nucleotide polymorphisms (SNPs) of DNA from peripheral venous blood were detected by Real-time PCR.The relationships of three genotypes'chemotherapy effect after two cycles of chemotherapy and the median time to progression were compared.Results:The effect rates of the three genotypes are:C/C 51.09%(47/92), C/T 38.04% (35/92), and T/T 10.87%(10/92), while the clinical benefit rates of chemotherapy and the median TTP of C/C and T/T+C/T genotypes were 76.59% , 6 months and 53.33%, 4 months, respectively.Conclusions:There is relationship between polymorphisms in XPG gene and therapeutic effect of oxaliplatin, which could be used as a guidance of the medication of oxaliplatin chemotherapy for gastric cancer.
出处
《现代生物医学进展》
CAS
2010年第14期2615-2618,共4页
Progress in Modern Biomedicine
基金
Natural Science Foundation of Shandong Province(Y2008C126)~~
关键词
XPG
基因多态性
胃癌
奥沙利铂
XPG
Gastric carcinoma
Polymorphism
Single nucleotide Polymorphism
Oxaliplatin